Dr. Falk Pharma Gmbh

Zedira Gmbh

Rudolf Wilhelm

Roland Greinwald

Markus Proels

Ralph Mueller

Markus Pröls

Erik Fischer

Ralf Pasternack

Wolfgang Mohr

Heidi Waenerlund Poulsen

Martin Hils

Ralf Mohrbacher

Tanju Nacak

Pröls Markus

Ralph Muller

Ansgar Boegershausen

Allan Kund Roepstorff

Christian Moliin Outzen Kapel

Bernhard Tewes

Markus Prols

Ralph Müller

Allan Knud Roepstorff

Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.

Pharmaceutical formulation for the treatment of inflammatory changes to the rectum

Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus

An optimized pharmaceutical formulation for the treatment of inflammatory diseases of the colon is disclosed, wherein the pharmaceutical formulation is a capsule containing pellets, which capsule is suitable for oral administration and delivers the active substance in a targeted manner to the site of action, namely the colon. This is achieved by a complex and multiple coating of pellets, which permit a modified release of active substance. The release of the active substance is at its maximum only in the colon, with at the same time low blood plasma levels. The results of the pharmaceutical tests concerning in vitro release are corroborated by the results in pharmaco-kinetic and clinical studies and the clinical efficacy demonstrated by these. The formulation according to the invention has a very good medicinal safety.

Pellets having a multi-layer structure for delayed release of the active substance in the distal colon

The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.

Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size

The present application describes a novel, advantageous purification method which guarantees the embryonation capability and the viability of a worm egg suspension. Theworm eggs are first treated in a non-embryonated condition in a sulfuric acid solution at about =ph 2. Bacteria and viruses are thereby killed successfully. The germination number of yeasts and fungi is reduced. In a second step, the pH-value is increased and an orally tolerated preservative is added. Yeasts and fungi are thereby killed successfully. The suspension medium used in the second purification step can then be used as a culture medium for additional production (embryonation) and storage.

Production of a viable, storable worm egg suspension

A method for determining the biological activity of embryonatedeggs is described, in which at least one of the following determinations is carried out:

[object Object]

The invention relates to an effervescent tablet for preparing a mouth rinsing solution, wherein the effervescent tablet exhibits a high release rate of budesonide. A high availability of the active ingredient during use as a mouth rinsing solution on the inflamed mucosa of the upper digestive tract is thereby achieved. The advantage of the formulation according to the invention lies in the bioavailability comparable to oral forms of administration, which allows the formulation to be used safely over an extended period of time.

Pharmaceutical formulation for treating the upper digestive tract

Growing community of inventors

Bischweier, Germany

Rudolf Wilhelm